The Impact of Preoperative Radiation Therapy on Locoregional Recurrence in Patients with Stage IV Rectal Cancer Treated with Definitive Surgical Resection and Contemporary Chemotherapy
- PMID: 26014718
- DOI: 10.1007/s11605-015-2861-9
The Impact of Preoperative Radiation Therapy on Locoregional Recurrence in Patients with Stage IV Rectal Cancer Treated with Definitive Surgical Resection and Contemporary Chemotherapy
Abstract
Purpose: Definitive resection of primary rectal cancers is frequently incorporated, with or without preoperative radiotherapy and perioperative chemotherapy, in the management of selected patients with metastatic rectal adenocarcinoma. This study reviews the impact of preoperative radiotherapy and perioperative chemotherapy on locoregional recurrence and overall survival in these patients.
Methods and materials: This retrospective study with an Institutional Review Board (IRB) waiver included 109 patients with metastatic rectal adenocarcinoma who underwent definitive primary resection between 1998 and 2011. In addition to resection, 64 patients were treated with preoperative radiotherapy and perioperative chemotherapy and 45 patients were treated with perioperative chemotherapy alone. Radiotherapy dose was typically 50.4 Gy. Baseline variables were compared using chi-square and unpaired t tests. Overall survival was calculated using Kaplan-Meier method. Univariate and multivariate analyses were performed using Cox proportional hazards regression.
Results: There were no significant baseline differences between the two groups. There was no significant difference in locoregional recurrence (10.9 vs. 11.1%; p = 0.90) or overall survival (34.5 vs. 34.8 months; p = 0.89) for patients treated with preoperative radiotherapy compared to those treated with perioperative chemotherapy alone, respectively. Patients who underwent radiotherapy were less likely to have a positive margin (10.9 vs. 20.0%; p = 0.19), lymphovascular invasion (32.8 vs. 53.3%; p = 0.03), and pathologic stage N2 disease (25.0 vs. 42.2%; p = 0.02). Grade 2 postoperative complications were more common in the preoperative radiotherapy group (32.8 vs. 15.6%; p = 0.04). Multivariate analysis demonstrated that patients with poorly differentiated tumors (HR 2.19; p = 0.009) and those that did not undergo liver-directed therapy (HR 2.20; p = 0.005) had inferior survival.
Conclusions: Locoregional recurrence is modest in patients with metastatic rectal adenocarcinoma receiving definitive primary resection, irrespective of the use of radiotherapy. Preoperative radiotherapy may enhance pathologic downstaging at the expense of increased grade 2 postoperative complications. Its use should be reserved for patients at high risk for locoregional recurrence.
Similar articles
-
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15. Lancet Oncol. 2015. PMID: 26189067 Clinical Trial.
-
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma.Clin Colorectal Cancer. 2020 Jun;19(2):116-122. doi: 10.1016/j.clcc.2020.02.005. Epub 2020 Feb 8. Clin Colorectal Cancer. 2020. PMID: 32173279 Free PMC article.
-
Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.J BUON. 2013 Apr-Jun;18(2):385-90. J BUON. 2013. PMID: 23818350
-
Neoadjuvant-intensified treatment for rectal cancer: time to change?World J Gastroenterol. 2013 May 28;19(20):3052-61. doi: 10.3748/wjg.v19.i20.3052. World J Gastroenterol. 2013. PMID: 23716984 Free PMC article.
-
Individual participant data pooled-analysis of risk factors for recurrence after neoadjuvant radiotherapy and transanal local excision of rectal cancer: the PARTTLE study.Tech Coloproctol. 2019 Sep;23(9):831-842. doi: 10.1007/s10151-019-02049-z. Epub 2019 Aug 6. Tech Coloproctol. 2019. PMID: 31388861
Cited by
-
Predicting Overall Survival in Patients with Metastatic Rectal Cancer: a Machine Learning Approach.J Gastrointest Surg. 2020 May;24(5):1165-1172. doi: 10.1007/s11605-019-04373-z. Epub 2019 Aug 29. J Gastrointest Surg. 2020. PMID: 31468331 Free PMC article.
-
Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer.Protein Cell. 2016 Feb;7(2):141-51. doi: 10.1007/s13238-015-0234-5. Epub 2016 Jan 12. Protein Cell. 2016. PMID: 26758252 Free PMC article.
-
Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?J Gastrointest Surg. 2021 Sep;25(9):2411-2422. doi: 10.1007/s11605-021-05042-w. Epub 2021 Jun 7. J Gastrointest Surg. 2021. PMID: 34100244 Review.
-
The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma.Oncotarget. 2015 Dec 22;6(41):43831-42. doi: 10.18632/oncotarget.6257. Oncotarget. 2015. PMID: 26517093 Free PMC article.
-
The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis.J Gastrointest Oncol. 2017 Aug;8(4):650-658. doi: 10.21037/jgo.2017.06.07. J Gastrointest Oncol. 2017. PMID: 28890815 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources